University of Pennsylvania - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
120
About the Report
About the Report
Summary
University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, criminology, fine arts, finance, operations and information management, telecommunications, theatre arts, and visual studies, among others. Its schools include school of arts and sciences, school of dental medicine, school of design, school of engineering and applied science, school of medicine and school of nursing. The university also offers arts, athletics, healthcare, libraries, online learning and global service facilities. UOP is headquartered in Philadelphia, Pennsylvania, the US.
University of Pennsylvania-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
University of Pennsylvania, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
University of Pennsylvania, Medical Devices Deals, 2012 to YTD 2018 13
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
University of Pennsylvania, Pharmaceuticals & Healthcare, Deal Details 18
Venture Financing 18
Carisma Therapeutics Raises USD53 Million in Series A Financing 18
Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 20
Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 22
Partnerships 24
Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 24
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 25
Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 26
Ophthotech and University of Pennsylvania Enter into Agreement 27
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 28
JW Pharma Enters into Agreement with University of Pennsylvania 29
Incyte Enters into Research Agreement with Abramson Cancer Center 30
Tempus Health Enters into Agreement with Penn Medicine 31
Liquid Biotech Enters into Research Agreement with University of Pennsylvania 32
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 33
Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 34
Biogen Enters into Co-Development Agreement with University of Pennsylvania 35
Seres Therapeutics Enters into Agreement with University of Pennsylvania 36
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 37
Genisphere Enters into Research Agreement with University of Pennsylvania 38
NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 39
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 40
Janssen Pharma Enters into Agreement with University of Pennsylvania 41
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 42
Epic Sciences Partners with Abramson Cancer Center 43
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 44
PTC Therapeutics Enters into Agreement with University of Pennsylvania 45
CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 46
Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 47
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 48
PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 49
Licensing Agreements 50
Precision BioSciences Enters into Licensing Agreement with University of Pennsylvania 50
Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 51
ImmunoRestoration Enters into Licensing Agreement with University of Pennsylvania 52
Arrakis Therapeutics Enters into Licensing Agreement with University of Pennsylvania 53
Expres2ion Biotech Enters into Licensing Agreement with University of Pennsylvania 54
Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 55
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 56
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 57
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 58
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 59
Cetazam Therapeutics Enters into Licensing Agreement with Perelman School of Medicine 60
Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 61
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 62
Novartis Enters Into Licensing Agreement With University of Pennsylvania For All CARs 63
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 65
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 66
Equity Offering 67
Tmunity Therapeutics Raises USD10 Million in Equity Financing 67
Asset Transactions 68
University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For USD 55 Million 68
Acquisition 69
University of Pennsylvania Health System To Acquire Chester County Hospital 69
University of Pennsylvania-Key Competitors 70
University of Pennsylvania-Key Employees 71
University of Pennsylvania-Locations And Subsidiaries 72
Head Office 72
Other Locations & Subsidiaries 72
Recent Developments 73
Government and Public Interest 73
Oct 03, 2018: Patient death following CAR-T therapy highlights serious manufacturing issues 73
Sep 24, 2018: National Institutes of Health names CHOP, Penn an undiagnosed diseases network site 75
Aug 24, 2018: Drs. Kellie Smith, Jeffrey Thompson, and Edwin Yau receive prestigious LUNGevity 2018 Career Development Awards 76
Aug 10, 2018: Cancer cells release biological 'drones' to fight immune system, research 77
Jul 30, 2018: Diabetes Drugs Act as Powerful Curb for Immune Cells in Controlling Disease-causing Inflammation 78
Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 79
Jun 28, 2018: Kidney Disease Patients' Experience Of Care And Illness Can Take A Large Emotional Toll 80
May 23, 2018: Foundation for Anesthesia Education and Research Awards USD 1.4 million in Grants 81
May 15, 2018: Penn Study Finds that Different Diseases Elicit Distinct Sets of Exhausted T Cells 84
Apr 25, 2018: Penn Bioinformatics Researcher Receives Big-Data Grant from the Chan Zuckerberg Initiative 85
Apr 24, 2018: Bacteria boost antifungal drug resistance in severe childhood tooth decay 86
Apr 23, 2018: New Cell Therapy Aids Heart Recovery Without Implanting Cells 88
Jan 30, 2018: New study shows severe toxicity with high-dose AAV9-based gene therapy in animal models 90
Dec 11, 2017: CAR T, Immunotherapy Bring New Hope for Multiple Myeloma Patients 91
Sep 27, 2017: Melanoma Cells Rewire Their Signaling Pathways to Resist Drug Treatment 93
Sep 26, 2017: PCORI Board approves USD 8.6 million for study on treatment options for psoriasis and USD 2.75 million for research on atrial fibrillation 94
Jul 18, 2017: New Combination of Anti-obesity Drugs may have Beneficial Effects 95
Jun 26, 2017: CRI Announces USD 1 Million Technology Impact Award Recipient 96
May 18, 2017: Researchers connect brain blood vessel lesions to intestinal bacteria 97
Feb 24, 2017: Penn Vet Team Identifies New Therapeutic Targets for the Tropical Disease Leishmaniasis 99
Product News 101
Sep 12, 2018: Regrowing dental tissue with stem cells from baby teeth 101
Aug 20, 2018: NCI-led research team develops predictor for immunotherapy response in melanoma 103
Mar 28, 2018: Progress in Quest to Develop a Human Memory Prosthesis 104
Mar 05, 2018: New Gene Therapy Corrects a Form of Inherited Macular Degeneration in Canine Model 106
Feb 20, 2018: Penn Engineers Test Drug Transfer Using Placenta-on-a-Chip 108
Feb 12, 2018: Penn Chemists Develop Motion Capture-like Technology for Tracking Protein Shape 110
Other Significant Developments 112
Sep 25, 2018: Susan G. Komen announces USD 26 million investment in new research to find solutions for aggressive and metastatic breast cancers, and to help communities most at risk 112
Aug 15, 2018: 'BOOST-3' Trial Seeks to Improve Outcomes After Severe Traumatic Brain Injury 114
Jul 09, 2018: Penn announces publication of clinically relevant genome editing in primates using precision's ARCUS platform 116
Jun 07, 2018: Blood test may identify pregnant women at risk of premature birth 117
Jun 04, 2018: Diuretic as effective as antibiotics to treat women's acne 118
Apr 10, 2018: Global Genes Partners with University of Pennsylvania Orphan Disease Center for 2018 RARE Patient Advocacy Symposium 119
Appendix 120
Methodology 120
About GlobalData 120
Contact Us 120
Disclaimer 120
List of Figure
List of Figures
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
University of Pennsylvania, Medical Devices Deals, 2012 to YTD 2018 13
List of Table
List of Tables
University of Pennsylvania, Pharmaceuticals & Healthcare, Key Facts 2
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
University of Pennsylvania, Deals By Therapy Area, 2012 to YTD 2018 11
University of Pennsylvania, Medical Devices Deals, 2012 to YTD 2018 13
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Carisma Therapeutics Raises USD53 Million in Series A Financing 18
Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 20
Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 22
Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 24
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 25
Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 26
Ophthotech and University of Pennsylvania Enter into Agreement 27
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 28
JW Pharma Enters into Agreement with University of Pennsylvania 29
Incyte Enters into Research Agreement with Abramson Cancer Center 30
Tempus Health Enters into Agreement with Penn Medicine 31
Liquid Biotech Enters into Research Agreement with University of Pennsylvania 32
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 33
Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 34
Biogen Enters into Co-Development Agreement with University of Pennsylvania 35
Seres Therapeutics Enters into Agreement with University of Pennsylvania 36
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 37
Genisphere Enters into Research Agreement with University of Pennsylvania 38
NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 39
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 40
Janssen Pharma Enters into Agreement with University of Pennsylvania 41
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 42
Epic Sciences Partners with Abramson Cancer Center 43
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 44
PTC Therapeutics Enters into Agreement with University of Pennsylvania 45
CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 46
Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 47
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 48
PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 49
Precision BioSciences Enters into Licensing Agreement with University of Pennsylvania 50
Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 51
ImmunoRestoration Enters into Licensing Agreement with University of Pennsylvania 52
Arrakis Therapeutics Enters into Licensing Agreement with University of Pennsylvania 53
Expres2ion Biotech Enters into Licensing Agreement with University of Pennsylvania 54
Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 55
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 56
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 57
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 58
Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 59
Cetazam Therapeutics Enters into Licensing Agreement with Perelman School of Medicine 60
Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 61
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 62
Novartis Enters Into Licensing Agreement With University of Pennsylvania For All CARs 63
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 65
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 66
Tmunity Therapeutics Raises USD10 Million in Equity Financing 67
University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For USD 55 Million 68
University of Pennsylvania Health System To Acquire Chester County Hospital 69
University of Pennsylvania, Key Competitors 70
University of Pennsylvania, Key Employees 71
University of Pennsylvania, Subsidiaries 72
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.